

## Supplementary Files

### S1. Search strategy used in different databases

PubMed	SCOPUS/EMBASE	WHO/Semantic Scholar
ALL ("COVID-19" OR "COVID-2019" OR "severe acute respiratory syndrome coronavirus 2" OR "severe acute respiratory syndrome coronavirus 2" OR "2019-nCoV" OR "nCoV" OR "SARS- CoV-2" OR "2019nCoV" OR "coronavirus") AND ALL ("clinical for epidemiological characterization" OR "Symptom" OR "Symptoms") AND ALL ("comorbidity" OR "comorbidities" AND full text[sb] AND ( "2019/12/31"[PDate] : "2020/04/20"[PDate] ) AND Humans[Mesh].	ALL ("COVID-19" OR "COVID-2019" OR "severe acute respiratory syndrome coronavirus 2" OR "severe acute respiratory syndrome coronavirus 2" OR "2019-nCoV" OR "nCoV" OR "SARS-CoV- 2" OR "2019nCoV" OR "coronavirus") AND ALL ("clinical for epidemiological characterization" OR "Symptom" OR "Sy- mptoms") AND ALL ("comorbidity" OR "comorbidities") AND (LIMIT- TO (LANGUAGE, "English")) AND (LIMI- TO (PUBYEAR, 2020)) AND (LIMIT- TO (DOCTYPE, "ar") OR LIMIT- TO (DOCTYPE, "re"))	("COVID-19" OR "COVID-2019" OR "severe acute respiratory syndrome coronavirus 2" OR "severe acute respiratory syndrome coronavirus 2" OR "2019-nCoV" OR "nCoV" OR "SARS-CoV-2" OR "2019nCoV" OR "coronavirus") AND ("clinical for epidemiological characterization" OR "Symptom" OR "Symptoms") AND ("comorbidity" OR "comorbidities")

### S2. Characteristics of studies that evaluated the prevalence and correlation of symptoms and comorbidities of the COVID-19 patients.

Authors	Publication Date	Country & Location	Study Design	Mean/	Patient No. (n)	Male (n)	Female (n)	Gender	Fever	Cough / Dry cough	Fatigue	Dyspnoea/ Shortness of breath	Headache	Diarrhoea
				Median										
			<b>Age</b>											
Wan et al.	21.3.2020	Chongqing, China	N/M	47	135	72	63	Both	0.89	0.77	0.33	0.13	0.33	0.13
Zhang et al.	18.2.2020	Wuhan, China	N/M	57	140	71	69	Both	0.79	0.64	0.64	0.31	N/M	0.13
Xu et al.	19.2.2020	Zhejiang, China	Retrospective	41	62	35	27	Both	0.77	0.81	0.52	N/M	0.34	0.08
Zhu et al.	13.3.2020	Anhui, China	Retrospective	46	32	15	17	Both	0.84	0.66	0.16	N/M	0.03	0.03
Chen et al.	16.02.2020	Wuhan, China	Retrospective	56	21	17	4	Both	0.99	0.80	0.85	0.52	0.10	0.20
Liu et al.	9.02.2020	Shenzhen, China	N/M	60	12	8	4	Both	0.83	0.92	N/M	N/M	N/M	0.17
Chen et al.	26.03.2020	Wuhan, China	Retrospective	62	274	171	103	Both	0.91	0.68	0.50	0.44	0.11	0.28
Mo et al.	16.3.2020	Wuhan, China	Retrospective, single center	54	155	86	69	Both	0.81	0.63	0.73	0.32	0.10	0.05
Liu et al.	07.02.2020	Hubei, China	Retrospective	57	137	61	76	Both	0.82	0.48	0.32	0.19	0.10	0.08
Jin et al.	24.03.2020	Zhejiang, China	Retrospective	46	651	331	320	Both	0.84	0.67	0.18	N/M	0.10	N/M
Wang et al.	17.03.2020	Wuhan, China	Retrospective, single center	56	138	75	63	Both	0.99	0.59	0.70	0.31	0.07	0.10
Yuan et al.	19.03.2020	Hubei, China	Retrospective	60	27	12	15	Both	0.78	0.59	N/M	0.41	N/M	N/M
Guan et al.	28.02.2020	China (30 provinces)	Cohort	47	1099	639	460	Both	0.89	0.68	0.38	N/M	0.14	0.04
Liu et al.	27.03.2020	Hainan, China	Retrospective	68	56	31	25	Both	0.76	0.36	0.09	N/M	N/M	N/M
Zhou et al.	12.03.2020	Wuhan, China	N/M	51	254	115	139	Both	0.84	0.39	0.52	0.04	0.11	N/M
Huang et al.	24.01.2019	Wuhan, China	Cohort	49	41	30	11	Both	0.98	0.76	0.44	0.55	0.08	0.03
Chen et al.	29.01.2019	Wuhan, China	Retrospective, single center	55.5	99	67	32	Both	0.83	0.82	N/M	N/M	0.08	0.02
Du et al.	3.04.2020	Wuhan, China	Retrospective	66	85	62	23	Both	0.92	0.22	0.59	0.71	0.05	0.19
Xu et al.	28.02.2020	Guangzhou, China	N/M	50	90	39	51	Both	0.78	0.63	0.21	N/M	0.04	0.06
Goyal et al.	17.04.2020	New York, USA	Retrospective	62	393	238	155	Both	0.77	0.79	N/M	0.57	N/M	0.24
Barrasa et al.	1.04.2020	Vitoria, Spain	N/M	63	48	27	21	Both	1.00	0.73	N/M	0.88	N/M	N/M
Yan et al.	12.4.2020	USA	Cross sectional	48.5	59	29	29	Both	0.70	0.66	0.81	0.54	0.66	0.48
Gupta et al.	6.04.2020	New Delhi, India	Retrospective, Observational	40	21	14	7	Both	0.43	0.43	N/M	N/M	0.14	N/M
Yang et al.	21.02.2020	Wenzhou, China	Retrospective cohort	45	149	81	68	Both	0.77	0.58	N/M	0.01	0.09	0.07
Han et al.	15.04.2020	Wuhan, China	Retrospective	62.5	206	91	115	Both	0.67	0.26	0.45	N/M	N/M	0.33
Kim et al.	6.04.2020	South Korea	Cohort	40	28	15	13	Both	0.25	0.29	0.11	N/M	0.25	0.11
Wang et al.	15.03.2020	Wuhan, China	Retrospective, single-centre	69	339	166	173	Both	0.92	0.53	0.40	0.41	0.04	0.13
Shi et al.	24.02.2020	Wuhan, China	Retrospective	49.5	81	42	39	Both	0.73	0.59	0.09	0.42	0.06	0.04
Yang et al.	21.02.2020	Wuhan, China	Retrospective, single-centre, Observational	60	52	35	17	Both	0.98	0.77	N/M	0.64	0.06	N/M

N/M: Not Mentioned

**S2 (Continued).** Characteristics of studies that evaluated the prevalence and correlation of symptoms and comorbidities of the COVID-19 patients.

Authors	Sore Throat	Myalgia/ Muscle Ache	Rhinorrhea	Cough/ Sputum Production	Chest tightness	Chest pain	Nausea	Vomiting	Abdominal Pain	Dizziness	Anorexia	Pharyngalgia	Hemoptysis	Others	No. of Symptoms
Wan et al.	N/M	0.33	N/M	0.09	N/M	N/M	N/M	N/M	N/M	N/M	0.18	0.03	Loss of appetite-4.4%, Palpitation-3.7%, Retching-3%	13	
Zhang et al.	N/M	N/M	N/M	N/M	0.31	N/M	0.17	N/M	0.06	N/M	0.17	N/M	N/M	N/M	9
Xu et al.	N/M	0.52	N/M	N/M	N/M	N/M	N/M	N/M	N/M	N/M	N/M	0.03	N/M	N/M	7
Zhu et al.	N/M	0.16	N/M	0.16	0.09	N/M	N/M	N/M	N/M	N/M	N/M	N/M	N/M	N/M	8
Chen et al.	N/M	0.40	N/M	N/M	0.55	N/M	N/M	N/M	N/M	N/M	N/M	N/M	N/M	N/M	8
Liu et al.	N/M	0.33	N/M	N/M	N/M	N/M	0.17	0.17	N/M	N/M	N/M	N/M	N/M	Chill- 42%	7
Chen et al.	N/M	0.22	N/M	0.30	0.38	N/M	0.09	0.06	0.07	0.08	0.24	0.04	0.03	N/M	16
Mo et al.	N/M	0.61	N/M	N/M	0.39	0.04	0.04	0.04	0.02	0.02	0.32	N/M	N/M	N/M	14
Liu et al.	N/M	0.32	N/M	0.04	N/M	N/M	N/M	N/M	N/M	N/M	N/M	N/M	0.05	Heart palpitation-7%	10
Jin et al.	0.15	0.11	N/M	0.35	N/M	N/M	N/M	N/M	N/M	N/M	N/M	N/M	0.02	Nasal Obstruction-6%,	9
Wang et al.	N/M	0.35	N/M	0.27	N/M	N/M	0.10	0.04	N/M	0.09	0.40	0.17	N/M	N/M	13
Yuan et al.	N/M	0.11	N/M	N/M	N/M	N/M	N/M	N/M	N/M	N/M	N/M	N/M	N/M	N/M	4
Guan et al.	0.14	0.15	N/M	0.34	N/M	N/M	0.05	0.05	N/M	N/M	N/M	N/M	0.01	Conjunctival congestion-1%, Nasal congestion-5%, Chills-11.5%, Throat congestion-2%, Tonsil swelling-2%, Rash-0.2%	17
Liu et al.	N/M	N/M	N/M	N/M	0.07	N/M	N/M	0.17	N/M	N/M	N/M	N/M	N/M	Nasal congestion-5%,	6
Zhou et al.	0.06	0.34	N/M	0.42	0.26	N/M	N/M	N/M	N/M	0.07	N/M	N/M	N/M	N/M	10
Huang et al.	N/M	0.44	N/M	0.28	N/M	N/M	N/M	N/M	N/M	N/M	N/M	N/M	0.05	N/M	9
Chen et al.	0.05	0.11	0.04	N/M	N/M	0.02	0.01	0.01	N/M	N/M	N/M	N/M	N/M	N/M	10
Du et al.	N/M	0.17	N/M	0.38	N/M	0.02	N/M	0.05	0.04	N/M	0.57	0.02	N/M	N/M	14
Xu et al.	0.26	0.28	N/M	0.12	N/M	N/M	0.06	0.02	N/M	N/M	N/M	N/M	N/M	Chills-7%	11
Goyal et al.	N/M	0.19	N/M	N/M	N/M	N/M	0.19	0.19	N/M	N/M	N/M	N/M	N/M	N/M	7
Barrasa et al.	N/M	0.04	N/M	N/M	N/M	N/M	N/M	N/M	N/M	N/M	N/M	N/M	N/M	Malaise-44%	5
Yan et al.	0.32	0.63	0.31	N/M	N/M	N/M	0.27	N/M	N/M	N/M	N/M	N/M	N/M	Nasal obstruction 47.5%, Anosmia 68%, Ageusia 71%	13
Gupta et al.	0.24	N/M	N/M	N/M	N/M	N/M	N/M	N/M	N/M	N/M	N/M	N/M	N/M	N/M	5
Yang et al.	0.14	0.03	N/M	0.32	0.10	0.03	0.01	0.01	N/M	N/M	N/M	N/M	N/M	Chill-14%, Snotty-3%	14
Han et al.	N/M	0.21	N/M	N/M	0.24	N/M	N/M	0.12	0.04	N/M	N/M	0.06	N/M	Poor apitite-34%	11
Kim et al.	0.29	0.25	0.07	0.21	N/M	N/M	N/M	N/M	0.04	N/M	N/M	N/M	N/M	N/M	10
Wang et al.	N/M	0.05	N/M	0.28	0.26	N/M	0.04	N/M	N/M	0.04	0.28	0.04	N/M	N/M	13
Shi et al.	N/M	N/M	0.26	0.19	0.22	N/M	N/M	0.05	N/M	0.02	0.01	N/M	N/M	N/M	12
Yang et al.	N/M	0.12	0.06	N/M	N/M	0.02	N/M	0.04	N/M	N/M	N/M	N/M	N/M	Malaise-35%, Arthralgia-2%	10

N/M: Not Mentioned

**S2 (Continued).** Characteristics of studies that evaluated the prevalence and correlation of symptoms and comorbidities in the nCOVID-19 patients.


Authors	Diabetes	Hypertension	Cardiovascular Disease	Coronary heart disease	Cerebrovascular disease	COPD /Lung disease	Chronic liver disease	Chronic Renal disease	Chronic Kidney disease	Malignancy	ARDS	Others	No. of Comorbidities
Wan et al.	0.09	0.10	0.05	N/M	N/M	0.007	0.02	N/M	N/M	0.03	N/M	N/M	6
Zhang et al.	0.12	0.30	N/M	0.05	N/M	0.014	0.06	0.01	N/M	N/M	N/M	Gastric ulcer & Hyperlepedemia-5%, Thyroid disease-3.6%, Urolithiasis-2.1%, Arrhythmia-3.6%, Cholilithiasis-4.3%	12
Xu et al.	0.02	0.08	N/M	N/M	0.02	0.020	0.11	0.02	N/M	N/M	N/M	N/M	6
Zhu et al.	0.13	0.22	N/M	0.06	0.03	0.060	0.06	0.03	N/M	N/M	N/M	Mental disorder- 3%, Tumor-6%	9
Chen et al.	0.14	0.24	N/M	N/M	N/M	N/M	N/M	N/M	N/M	N/M	N/M	N/M	2
Liu et al.	0.08	0.25	N/M	0.33	N/M	0.080	N/M	0.08	N/M	N/M	N/M	Bacterial co infection-17%, Pneumonia-100%,	7
Chen et al.	0.17	0.34	0.08	N/M	0.01	0.070	N/M	N/M	0.01	0.03	N/M	HBV infection-4%, Metabolic arthritis & Autoimmune disease & Gastro Intestinal disease- 1%	11
Mo et al.	0.10	0.24	0.10	N/M	0.05	0.030	0.05	0.04	N/M	0.05	N/M	Tuberculosis-2%, HIV-1%	10
Liu et al.	0.10	0.10	0.07	N/M	N/M	0.015	N/M	N/M	N/M	0.02	N/M	N/M	5
Jin et al.	0.07	0.15	N/M	0.01	N/M	0.002	0.04	0.01	N/M	0.01	N/M	Immunosuppression-0.17%,	8
Wang et al.	0.10	0.31	0.15	N/M	0.05	0.030	0.03	N/M	0.03	0.07	N/M	HIV infection-1%	9
Yuan et al.	0.22	0.19	0.11	N/M	N/M	N/M	N/M	N/M	N/M	N/M	0.41	Tumor & Cerebral infarction & Chronic gastric- 4%	9
Guan et al.	0.07	0.15	N/M	0.03	0.01	0.010	N/M	0.01	N/M	0.01	N/M	Hepatitis B Infection-2%, Immune deficiency-0.2%,	9
Liu et al.	0.07	0.17	N/M	0.11	N/M	N/M	0.06	N/M	0.03	N/M	N/M	Persistent arterial fibrillation-6%,	6
Zhou et al.	0.10	0.25	0.05	0.07	N/M	0.020	0.01	N/M	0.01	N/M	N/M	HIV infection-0.4%,	8
Huang et al.	0.20	0.15	0.15	N/M	N/M	0.020	0.02	N/M	N/M	0.02	N/M	N/M	6
Chen et al.	N/M	N/M	N/M	N/M	N/M	N/M	N/M	0.03	N/M	N/M	0.17	Acute Respiratory Injury-8%, Septic shock-4%, Pneumonia-1%	5
Du et al.	0.22	0.38	0.08	0.12	N/M	0.020	0.06	N/M	0.04	0.07	N/M	N/M	8
Xu et al.	0.06	0.19	0.03	N/M	N/M	0.010	N/M	N/M	N/M	0.02	N/M	Tuberculosis-2%,	6
Goyal et al.	0.25	0.50	N/M	0.14	N/M	0.050	N/M	N/M	N/M	N/M	N/M	Asthama-12.5%, Obesity-35%	6
Barrasa et al.	0.19	0.44	N/M	0.10	N/M	0.380	N/M	N/M	N/M	N/M	1.00	Obesity-48%, Immunosuppression-3%	7
Yan et al.	0.09	0.14	0.05	N/M	N/M	0.050	N/M	N/M	N/M	0.04	N/M	Allergic rhinitis-34%, Sinus disease 3%	7
Gupta et al.	0.14	0.24	N/M	N/M	N/M	N/M	N/M	N/M	N/M	N/M	N/M	Anxity-5%, Hypothyroidism-5%, Migrane-5%, Obstructive sleep aponea-5%	6
Yang et al.	N/M	N/M	0.19	N/M	0.19	N/M	N/M	N/M	N/M	N/M	N/M	Respiratory system disease - 0.67%, Digestive system disease- 5%, Endocrine disease- 6%	5
Han et al.	0.10	0.27	N/M	N/M	0.08	0.040	N/M	N/M	N/M	N/M	N/M	N/M	4
Kim et al.	0.07	N/M	N/M	N/M	N/M	N/M	0.04	N/M	N/M	0.04	N/M	Obesity-18%, Asthama-4%	5
Wang et al.	0.16	0.41	0.16	N/M	0.06	0.060	0.01	N/M	0.04	0.04	N/M	Autoimmune disease- 1.5%	9
Shi et al.	0.12	0.15	0.10	N/M	0.07	0.110	0.09	0.04	N/M	0.05	N/M	N/M	8
Yang et al.	0.35	N/M	0.23	N/M	N/M	N/M	0.29	N/M	0.29	N/M	0.67	Urinary tract infection-2%, Gastrointestinal haemorrhage-4%	7

N/M: Not Mentioned

## Overall Meta-analysis of the clinical symptoms and comorbidities


### Symptoms

#### S3. Fever




#### S4. Cough / Dry Cough

Meta-analysis of the prevalence of clinical symptom (Cough) in COVID-19 infected patients




## S5. Fatigue/Weakness

Meta-analysis of the prevalence of clinical symptom (Fatigue) in COVID-19 infected patients




## S6. Dyspnea/Shortness of breath

Meta-analysis of the prevalence of clinical symptom (Dyspnea) in COVID-19 infected patients




## S7. Headache


Meta-analysis of the prevalence of clinical symptom (Headache) in COVID-19 infected patients



## S8. Diarrhea




## S9. Sore Throat




## S10. Myalgia/Muscle Ache


Meta-analysis of the prevalence of clinical symptom (Myalgia) in COVID-19 infected patients



## S11. Rhinorrhea




## S12. Sputum Production/Expectoration




### S13. Chest tightness

Meta-analysis of the prevalence of clinical symptom (Chest Tightness) in COVID-19 infected patients




### S14. Chest pain


Meta-analysis of the prevalence of clinical symptom (Chest Pain) in COVID-19 infected patients




## S15. Nausea




## S16. Vomiting



## S17. Abdominal Pain




## S18. Dizziness




## S19. Anorexia

Meta-analysis of the prevalence of clinical symptom (Anorexia) in COVID-19 infected patients




## S20. Pharyngalgia

Meta-analysis of the prevalence of clinical symptom (Pharyngalgia) in COVID-19 infected patients




## S21. Haemoptysis




## Comorbidity


### S22. Diabetes




## S23. Hypertension




## S24. Cardiovascular Disease




## S25. Coronary heart disease




## S26. Cerebrovascular disease




## S27. COPD/Lung disease




## S28. Chronic liver disease




## S29. Chronic Renal disease




## S30. Chronic Kidney disease



### S31. Malignancy



### S32. ARDS




## Subgroup meta-analysis by Age group

### Symptoms


#### S33. Fever

Meta-analysis of the prevalence of clinical symptom (Fever) in COVID-19 infected patients  
(stratified according to age group)




**S34. Cough/Dry Cough**

Meta-analysis of the prevalence of clinical symptom (Cough/Dry Cough) in COVID-19 infected patients  
(stratified according to age group)




**S35. Fatigue/weakness**

Meta-analysis of the prevalence of clinical symptom (Fatigue/Weakness) in COVID-19 infected patients  
(stratified according to age group)




### S36. Dyspnea/Shortness of Breath

Meta-analysis of the prevalence of clinical symptom (Dyspnea/Shortness of breath) in COVID-19 infected patients (stratified according to age group)




**S37. Headache**

Meta-analysis of the prevalence of clinical symptom (Headache) in COVID-19 infected patients  
(stratified according to age group)




**S38. Myalgia/Muscle Ache**


Meta-analysis of the prevalence of clinical symptom (Myalgia/Muscle Ache) in COVID-19 infected patients  
(stratified according to age group)



### S39. Rhinorrhea




### S40. Sputum Production / Expectoration




#### S41. Chest Tightness

Meta-analysis of the prevalence of clinical symptom (Chest Tightness) in COVID-19 infected patients  
(stratified according to age group)




#### S42. Nausea


Meta-analysis of the prevalence of clinical symptom (Nausea) in COVID-19 infected patients  
(stratified according to age group)




#### S43. Vomiting




#### S44. Abdominal Pain



#### S45. Anorexia




#### S486. Pharyngalgia



## S47. Haemoptysis


Meta-analysis of the prevalence of clinical symptom (Haemoptysis) in COVID-19 infected patients  
(stratified according to age group)



## Comorbidity


### S48. Diabetes

Meta-analysis of the prevalence of clinical comorbidity (Diabetes) in COVID-19 infected patients  
(stratified according to age group)




## S49. Hypertension

Meta-analysis of the prevalence of clinical comorbidity (Hypertension) in COVID-19 infected patients  
(stratified according to age group)




## S50. Cardiovascular Disease


Meta-analysis of the prevalence of clinical comorbidity (Cardiovascular Disease) in COVID-19 infected patients  
(stratified according to age group)




## S51. Coronary heart disease




## S52. Cerebrovascular disease




### S53. COPD/Lung disease




### S54. Chronic Liver disease



## S55. Chronic Kidney disease




## S56. Chronic Renal Disease



## S57. Malignancy


Meta-analysis of the prevalence of clinical comorbidity (Malignancy) in COVID-19 infected patients  
(stratified according to age group)



## Forest Plot of the Subgroup meta-analysis by Geographical Location


### Symptoms

#### S58. Fever




**S59. Cough/ Dry Cough**

Meta-analysis of the prevalence of clinical symptom (Cough) in COVID-19 infected patients  
(stratified according to geographical location)




**S60. Fatigue**




## S61. Dyspnea / Shortness of breath


Meta-analysis of the prevalence of clinical symptom (Dyspnea) in COVID-19 infected patients  
(stratified according to geographical location)




## S62. Headache




## S63. Diarrhea



#### S64. Sore throat




Meta-analysis of the prevalence of clinical symptom (Myalgia) in COVID-19 infected patients  
(stratified according to geographical location)




**S66. Nausea**

Meta-analysis of the prevalence of clinical symptom (Nausea) in COVID-19 infected patients  
(stratified according to geographical location)




## S67. Abdominal Pain




## Comorbidity:

### S68. Diabetes




## S69. Hypertension

Meta-analysis of the prevalence of clinical comorbidity (Hypertension) in COVID-19 infected patients  
(stratified according to geographical location)




## S70. Cardiovascular disease

Meta-analysis of the prevalence of clinical comorbidity (Cardiovascular Disease) in COVID-19 infected patients  
(stratified according to geographical location)




## S71. Coronary heart disease

Meta-analysis of the prevalence of clinical comorbidity (Coronary Heart Disease) in COVID-19 infected patients  
(stratified according to geographical location)




## S72. COPD / Lung disease


Meta-analysis of the prevalence of clinical comorbidity (COPD) in COVID-19 infected patients  
(stratified according to geographical location)




### S73. Chronic Liver Disease



### S74. Malignancy







### Funnel Plots of the symptoms and comorbidities

#### Symptoms


##### S76. Fever




##### S77. Cough / Dry cough




##### S78. Fatigue/ Weakness




**S79. Dyspnea/ Shortness of breath**









**S80. Headache**









**S81. Diarrhea**









**S82. Sore Throat****S83. Myalgia / Muscle Ache****S84. Rhinorrhea**




**S85. Sputum Production/Expectoration****S86. Chest Tightness****S87. Chest Pain**

**S88. Nausea****S89. Vomiting****S90. Abdominal pain**


**S91. Dizziness****S92. Anorexia****S93. Pharyngalgia**

**S94. Haemoptysis****Comorbidity****S95. Diabetes****S96. Hypertension**


**S97. Cardiovascular disease****S98. Coronary heart disease****S99. Cerebrovascular disease**

**S100. COPD / Lung disease****S101. Chronic Liver disease****S102. Chronic Renal disease**

**S103. Chronic Kidney disease**



**S104. Malignancy**



**S105. ARDS**

